Working… Menu

Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01678027
Recruitment Status : Active, not recruiting
First Posted : September 3, 2012
Last Update Posted : October 28, 2020
Information provided by (Responsible Party):
Il Ju Choi, National Cancer Center, Korea

Brief Summary:
This study evaluate whether treatment of Helicobacter pylori infection reduces the incidence of gastric cancer in subjects with family history of gastric cancer.

Condition or disease Intervention/treatment Phase
Gastric Cancer Helicobacter Pylori Infection Family Members Drug: Placebo Drug: LAC triple therapy Phase 3

Detailed Description:

Helicobacter pylori infection is associated with gastric cancer in epidemiological studies. However, it is still unknown whether H. pylori eradication is useful and required to prevent gastric cancer.

Gastric cancer risk is increased in family members of gastric cancer patient. Though there is no direct evidence that H. pylori infection is a risk factor for gastric cancer in family members of gastric cancer, current European guideline recommends H. pylori eradication in first-degree relatives of gastric cancer patients.

In this study, the investigators will evaluate whether H. pylori eradication can reduce gastric cancer risk in the first-degree family members of gastric cancer patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1838 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Helicobacter Pylori Eradication to Prevent Gastric Cancer in Subjects With Family History of Gastric Cancer: A Randomized Controlled Study
Study Start Date : November 2004
Actual Primary Completion Date : December 2018
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stomach Cancer

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo for LAC triple therapy
Drug: Placebo
Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.

Active Comparator: LAC triple therapy
PPI (Lansoprazole), Clarithromycin, Amoxicilline
Drug: LAC triple therapy
Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.
Other Name: PPI-Clarithromycin containing triple therapy

Primary Outcome Measures :
  1. Gastric cancer incidence [ Time Frame: 6 years after last participant enrollment ]

    The incidence of gastric cancer will be compared between the two arms as the participant assigned into either LAC treatment group or placebo group regardless the final H. pylori infection status.

    Currently, efficacy of LAC triple therapy shows about 75-85% eradication rate of the H. pylori.

Secondary Outcome Measures :
  1. Gastric dysplasia incidence [ Time Frame: 6 year after last participant enrollment ]
    Incidence of gastric dysplasia according to the H. pylori treatment

  2. Gastric cancer incidence between H. pylori treatment and H. pylori uninfected groups [ Time Frame: 6 year after last participant enrollment ]
    Gastric cancer incidence between H. pylori treatment group and H. pylori uninfected group

  3. Gastric cancer incidence according to H. pylori status [ Time Frame: 6 year after last participant enrollment ]
    Gastric cancer incidence between H. pylori eradicated group and H. pylori persistent group

  4. All-cause mortality [ Time Frame: 6 year after last participant enrollment ]
    All-cause mortality between H. pylori treatment group and placebo group

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Sibling or offspring of patients with gastric adenocarcinoma confirmed by EGD and biopsy
  • Informed consent should be signed

Exclusion Criteria:

  • Gastric cancer history
  • Other malignancy within the past 5 years
  • Hereditary cancer family member (HNPCC, FAP)
  • Peptic ulcer history
  • Peptic ulcer, esophageal cancer, gastric cancer case found at EGD
  • H. pylori eradication treatment history
  • Previous serious side effect to antibiotics
  • Serious concurrent infection or nonmalignant disease such as liver cirrhosis, renal failure, cardiovascular diseases
  • Pregnant or nursing women
  • Psychiatric disorder that would preclude compliance, alcoholics
  • Refuse informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01678027

Layout table for location information
Korea, Republic of
National Cancer Center, Korea
Goyang, Gyeonggi, Korea, Republic of, 10408
Sponsors and Collaborators
National Cancer Center, Korea
Layout table for investigator information
Principal Investigator: Il Ju Choi, M.D., Ph.D. National Cancer Center, Korea
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Il Ju Choi, M.D., Ph.D, National Cancer Center, Korea Identifier: NCT01678027    
Other Study ID Numbers: NCCCTS04-103
First Posted: September 3, 2012    Key Record Dates
Last Update Posted: October 28, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Il Ju Choi, National Cancer Center, Korea:
Stomach neoplasm
Helicobacter pylori
Additional relevant MeSH terms:
Layout table for MeSH terms
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors